‘Babesiosis occurrence among the U.S. Medicare Beneficiaries Ages 65 and Older, During 2006-2017: Overall, and by State and County of Residence’

FDA/CBER scientists in collaboration with CMS and Acumen LLC have published a population-based study titled 'Babesiosis occurrence among the U.S. Medicare Beneficiaries Ages 65 and Older, During 2006-2017: Overall, and by State and County of Residence' The study evaluated babesiosis trends: nationwide, and within and outside the seven well-established endemic states (CT, MA, RI, NJ, NY, MN, WI). To help identify predominance of local vs. travel-associated Babesia infection transmission, scientists also investigated state-of-service distribution for cases residing in the highest babesiosis-rate states. Results of our 12-year nationwide population-based study show substantially increasing babesiosis diagnosis trends during 2006-2017 in the well-established babesiosis-endemic areas and outside (e.g., NH, ME, VT, PA). This study highlights the utility of the real-world evidence (e.g., large Medicare administrative data) as a tool for better understanding national, state, local, seasonal, and other babesiosis or rare disease transmission patterns in support of public health efforts in the United States. Find out more about Babesiosis at CDC Babesiosis is a rare disease Rare Disease Day 2021   Manage Subscriptions  |  Unsubscribe All  |  Help This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA